HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-08-0269v1 16/3/1017    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Gorshtein, A. Articles by Shimon, I. PubMed PubMed Citation Articles by Gorshtein, A. Articles by Shimon, I.

¹ Institute of Endocrinology and Metabolism and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petach Tikva 49100, Israel
² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
³ Department of Internal Medicine E, Meir Hospital, Kfar Saba, Israel
⁴ Department of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany
⁵ Department of Neurosurgery, Sheba Medical Center, Tel-Hashomer, Israel

(Correspondence should be addressed to I Shimon; Email: ilanshi{at}clalit.org.il)

^* (A Gorshtein and H Rubinfeld contributed equally to this work)

The effect of mammalian target of rapamycin (mTOR) inhibitors on pituitary tumors is unknown. Akt overexpression was demonstrated in pituitary adenomas, which may render them sensitive to the anti-proliferative effects of these drugs. The objective of the study was to evaluate the anti-proliferative efficacy of the mTOR inhibitor, rapamycin, and its orally bioavailable analog RAD001 on the GH-secreting pituitary tumor GH3 and MtT/S cells and in human GH-secreting pituitary adenomas (GH-omas) in primary cell cultures. Treatment with rapamycin or RAD001 significantly decreased the number of viable cells and cell proliferation in a dose- and time-dependent manner. This was reflected by decreased phosphorylation levels of the downstream mTOR target p70S6K. Rapamycin treatment of GH3 cells induced G0/G1 cell cycle arrest. In other tumor cell types, this was attributed to a decrease in cyclin D1 levels. However, rapamycin did not affect cyclin D1 protein levels in GH3 cells. By contrast, it decreased cyclin D3 and p21/CIP, which stabilizes cyclin D/cyclin-dependent kinase 4 (cdk4) complexes. Rapamycin inhibited FCS-induced retinoblastoma phosphorylation and subsequent E2F-transcriptional activity. In response to decreased E2F activity, the expression of the E2F-regulated genes cyclin E and cdk2 was reduced. Our results showed that mTOR inhibitors potently inhibit pituitary cell proliferation, suggesting that mTOR inhibition may be a promising anti-proliferative therapy for pituitary adenomas. This therapeutic manipulation may have beneficial effects particularly for patients harboring invasive pituitary tumors resistant to current treatments.

This article has been cited by other articles:

				M. C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M. R. Ambrosio, M. Lapparelli, M. Scanarini, and E. C. degli Uberti Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 968 - 976. [Abstract] [Full Text] [PDF]

				V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G. K. Stalla, and M. Theodoropoulou The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells Cancer Res., January 15, 2010; 70(2): 666 - 674. [Abstract] [Full Text] [PDF]